This case report not only presents a compelling example of the potential that futibatinib holds for treating FGFR-2-mutated ACC but also emphasizes the importance of genetic testing and patient autonomy in tailoring treatment strategies. This evidence concerns the gene FGFR2 and adrenal cortex carcinoma.